+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. The Multicenter Study Group



Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. The Multicenter Study Group



Acta Haematologica 87(1-2): 22-28



The toxicity and hematologic effects of Escherichia coli-derived recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) were studied in 58 treatment cycles in Japanese patients with advanced malignancy as a phase I/II clinical trial. rhGM-CSF in doses from 30 to 250 micrograms/m2/day was administered by 24-hour continuous intravenous infusion, 8-hour intravenous, or a daily subcutaneous injection for 14 days. The most common adverse drug events (ADE) were fever, nausea/vomiting, diarrhea, skin eruption, and phlebitis. The frequency of moderate and severe ADE was 2.9, 14.7, 35.3 and 47.1% at 30, 60, 125, 250 micrograms/m2/day, respectively. In terms of administration routes, the frequency of ADE was 69% with 24-hour continuous intravenous infusion, 39.1% with 8-hour intravenous infusion and 16.7% with subcutaneous injection. Regarding the hematologic effects of rhGM-CSF, leukopenia improved in a dose-dependent manner. The appropriate dose level to be used in the phase II study was estimated to be in the range between 60 and 250 micrograms/m2/day.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040963717

Download citation: RISBibTeXText

PMID: 1585768


Related references

Phase i ii study of recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Bulletin du Cancer (Paris) 80(5): 418-430, 1993

Phase l/ll Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. Journal of Clinical Oncology 7(2): 159-167, 1989

Effects of bacterially synthesized recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Annals of Internal Medicine 110(5): 357-364, 1989

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Institute Mitteilungen 1988(83): 119-124, 1988

Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors. Bulletin du Cancer 80(5): 418-430, 1993

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Annals of Hematology 64(4): 173-180, 1992

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Annals of Hematology 64(6): 312-312, 1992

Double-blind, randomized comparison of the safety profile of granulocyte macrophage colony stimulating factor vs recombinant granulocyte colony stimulating factor in advanced HIV infected patients with neutropenia. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33: 246, 1993

Recombinant human granulocyte-colony stimulating factor and recombinant human macrophage-colony stimulating factor synergize in vivo to enhance proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in mice. Journal of Cellular Biochemistry 38(2): 127-136, 1988

Hematologic effects of recombinant human granulocyte macrophage colony stimulating factor and interleukin-6 administered to patients with malignancy. Blood 84(10 Suppl. 1): 598A, 1994

Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93(8): 2653-2659, 1999

Stimulation of granulopoiesis in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor: assessment of two routes of administration. Journal of Biological Response Modifiers 9(5): 475-479, 1990